Prevalence, incidence, evolution and associated factors of sleep paralysis in a longitudinal study of the US general population
Source : https://www.sciencedirect.com/science/article/abs/pii/S1389945722010346?via=ihub
First longitudinal study to estimate the incidence of sleep paralysis in the general population. * The risk of developing sleep paralysis at follow-up is predicted by symptoms associated with narcolepsy....
Discussion: Episodes of SP are frequent in the general population. Its persistence is predicted by several factors associated with narcolepsy like hypersomnolence and cataplexy but also by other factors like posttraumatic stress disorder or pain.
pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy | Published in Health Psychology Research
Sarfraz N, Okuampa D, Hansen H, et al. pitolisant, a novel histamine-3 receptor competitive antagonist, and inverse agonist, in the treatment of excessive daytime sleepiness in adult patients with narcolepsy....
Conclusion/Relevance: Recent phase II and III trials have shown that Pitolisant helps reduce the ESS score and cataplexy. In summary, based on comparative studies, recent evidence has shown that Pitolisant is non-inferior to Modafinil in the treatment of EDS but superior to Modafinil in reducing cataplexy.
Assessment of the effect of the dual orexin receptor antagonist daridorexant on various indices of disease severity in patients with mild to moderate obstructive sleep apnea
Source : https://www.sciencedirect.com/science/article/pii/S1389945722000399?via=ihub
Daridorexant did not impact AHI and SpO 2 in patients with mild/moderate OSA. * A comprehensive evaluation was performed of different indices of OSA severity. * The results of the...
Conclusion: These results suggest safe use of daridorexant in patients with mild to moderate OSA.
Abuse Potential of Lemborexant, a Dual Orexin Receptor Antagonist, Compared With Zolpidem and Suvorexant in Recreational Sedative Users - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35749758/
For all doses, LEM demonstrated abuse potential versus PBO and appeared to have a similar abuse potential profile to ZOL and SUV in this study population. Lemborexant was well tolerated....
Conclusions: For all doses, LEM demonstrated abuse potential versus PBO and appeared to have a similar abuse potential profile to ZOL and SUV in this study population. Lemborexant was well tolerated. Lemborexant has been placed in Schedule IV, the same drug schedule as ZOL and SUV.
The orexin story, sleep and sleep disturbances - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35698789/
The orexins, also known as hypocretins, are two neuropeptides (orexin A and B or hypocretin 1 and 2) produced by a few thousand neurons located in the lateral hypothalamus that...
Conclusion/Relevance: Several orexin receptor antagonists were recently developed as new drugs for insomnia, and orexin agonists may be the next-generation drugs for narcolepsy. Given the broad range of functions of the orexin system, these drugs might also be beneficial for treating various conditions other than sleep disorders in the near...
-
Dr Hamid4yrorexin may have multiple therapeutic applications